Disposition and metabolite kinetics of oral L-carnitine in humans

Journal of Clinical Pharmacology

Volumn 46, Issue 10, 2006, Pages 1163-1170

  Bain, Marcus A ^a   Milne, Robert W ^a   Evans, Allan M ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Gas chromatography; L carnitine; N nitrosodimethylamine; Trimethylamine; Trimethylamine N oxide

Indexed keywords

CARNITINE; DRUG METABOLITE; TRIMETHYLAMINE; TRIMETHYLAMINE OXIDE;

ADULT; ARTICLE; DIARRHEA; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE REGIMEN; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; KIDNEY TUBULE ABSORPTION; MALE; METABOLISM; NAUSEA; NORMAL HUMAN;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CARNITINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KIDNEY; MALE; METABOLIC CLEARANCE RATE; METHYLAMINES; NAUSEA; TASTE DISORDERS; VITAMIN B COMPLEX;

EID: 33748653981     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006292851     Document Type: Article

References (54)

1. Vaz FM, Wanders RJ. Carnitine biosynthesis in mammals. Biochem J. 2002;361:417-429.
2. Rebouche CJ, Paulson DJ. Carnitine metabolism and function in humans. Annu Rev Nutr. 1986;6:41-66.
3. Ohashi R, Tamai I, Nezu J, et al. Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol. 2001;59:358-366.
4. Lahjouji K, Mitchell GA, Qureshi IA. Carnitine transport by organic cation transporters and systemic carnitine deficiency. Mol Genet Metab. 2001;73:287-297.
5. Wang Y, Ye J, Ganapathy V, Longo N. Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency. Proc Natl Acad Sci U S A. 1999;96:2356-2360.
6. Willner JH, Ginsburg S, Dimauro S. Active transport of carnitine into skeletal muscle. Neurology. 1978;28:721-724.
7. Pierpont ME, Breningstall GN, Stanley CA, Singh A. Familial carnitine transporter defect: a treatable cause of cardiomyopathy in children. Am Heart J. 2000;139:S96-S106.
8. Stanley CA, DeLeeuw S, Coates PM, et al. Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake. Ann Neurol. 1991;30:709-716.
9. Bahl JJ, Bressler R. The pharmacology of carnitine. Annu Rev Pharmacol Toxicol. 1987;27:257-277.
10. Duran M, Loof NE, Ketting D, Dorland L. Secondary carnitine deficiency. J Clin Chem Clin Biochem. 1990;28:359-363.
11. Bernardini I, Rizzo WB, Dalakas M, Bernar J, Gahl WA. Plasma and muscle free carnitine deficiency due to renal Fanconi syndrome. J Clin Invest. 1985;75:1124-1130.
12. Leschke M, Rumpf KW, Eisenhauer T, et al. Quantitative assessment of carnitine loss during hemodialysis and hemofiltration. Kidney Int Suppl. 1983;24:S143-S146.
13. Evans AM, Faull R, Fornasini G, et al. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis. Clin Pharmacol Ther. 2000;68:238-249.
14. Huang W, Shaikh SN, Ganapathy ME, et al. Carnitine transport and its inhibition by sulfonylureas in human kidney proximal tubular epithelial cells. Biochem Pharmacol. 1999;58:1361-1370.
15. +-carnitine cotransporter hOCTN2. Am J Physiol Renal Physiol. 2000;279:F584-F591.
16. Tein I, DiMauro S, Xie ZW, De Vivo DC. Valproic acid impairs carnitine uptake in cultured human skin fibroblasts. An in vitro model for the pathogenesis of valproic acid-associated carnitine deficiency. Pediatr Res. 1993;34:281-287.
17. Wu X, Huang W, Prasad PD, et al. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999;290:1482-1492.
18. Bremer J. Carnitine-metabolism and functions. Physiol Rev. 1983;63:1420-1480.
19. Carnitor tablets and oral solution [product information; 03/04 OFS-6]. Gaithersburg, MD: Sigma-Tau Pharmaceuticals Inc; 2004.
20. Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th edition. New York, NY: McGraw-Hill; 2001.
21. Harper P, Elwin CE, Cederblad G. Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. Eur J Clin Pharmacol. 1988;35:69-75.
22. Hamilton JW, Li BU, Shug AL, Olsen WA. Carnitine transport in human intestinal biopsy specimens: demonstration of an active transport system. Gastroenterology. 1986;91:10-16.
23. McCloud E, Ma TY, Grant KE, Mathis RK, Said HM. Uptake of L-carnitine by a human intestinal epithelial cell line, Caco-2. Gastroenterology. 1996;111:1534-1540.
24. Seim H, Schulze J, Strack E. Catabolic pathways for high-dosed L(-)- or D(+)-carnitine in germ-free rats? Biol Chem Hoppe-Seyler. 1985;366:1017-1021.
25. Rebouche CJ, Mack DL, Edmonson PF. L-Carnitine dissimilation in the gastrointestinal tract of the rat. Biochemistry. 1984;23:6422-6426.
26. Lang DH, Yeung CK, Peter RM, et al. Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. Biochem Pharmacol. 1998;56:1005-1012.
27. Rebouche CJ. Quantitative estimation of absorption and degradation of a carnitine supplement by human adults. Metabolism. 1991;40:1305-1310.
28. Rebouche CJ, Chenard CA. Metabolic fate of dietary carnitine in human adults: identification and quantification of urinary and fecal metabolites. J Nutr. 1991;121:539-546.
29. Al-Waiz M, Ayesh R, Mitchell SC, Idle JR, Smith RL. Disclosure of the metabolic retroversion of trimethylamine N-oxide in humans: a pharmacogenetic approach. Clin Pharmacol Ther. 1987;42:608-612.
30. Magee PN, Barnes JM. The production of malignant primary hepatic tumours in the rat by feeding dimethylnitrosamine. Br J Cancer. 1956;10:114-122.
31. Lijinsky W, Keefer L, Conrad E, Van de Bogart R. Nitrosation of tertiary amines and some biologic implications. J Natl Cancer Inst. 1972;49:1239-1249.
32. Ohshima H, Kawabata T. Mechanism of N-nitrosodimethylamine formation from trimethylamine and trimethylaminoxide. IARC Sci Publ. 1978;19:143-153.
33. Simenhoff ML. Metabolism and toxicity of aliphatic amines. Kidney Int Suppl. 1975;7:S314-S317.
34. Simenhoff ML, Saukkonen JJ, Burke JF, et al. Importance of aliphatic amines in uremia. Kidney Int Suppl. 1978:316-519.
35. Humbert JR, Hammond KB, Hathaway WE, Marcoux JG, O'Brien D. Trimethylaminuria: the fish-odour syndrome. Lancet. 1970;2:770-771.
36. Mitchell SC, Smith RL. Trimethylaminuria: the fish malodor syndrome. Drug Metab Dispos. 2001;29:517-521.
37. Cashman JR, Camp K, Fakharzadeh SS, et al. Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria. Curr Drug Metab. 2003;4:151-170.
38. Longo A, Bruno G, Curti S, Mancinelli A, Miotto G. Determination of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine in human plasma by high-performance liquid chromatography after pre-column derivatization with 1-aminoanthracene. J Chromatogr B Biomed Appl. 1996;686:129-139.
39. Bain MA, Faull R, Fornasini G, Milne RW, Schumann R, Evans AM. Quantifying trimethylamine and trimethylamine-N-oxide in human plasma: interference from endogenous quaternary ammonium compounds. Anal Biochem. 2004;334:403-405.
40. Mills GA, Walker V, Mughal H. Quantitative determination of trimethylamine in urine by solid-phase microextraction and gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl. 1999;723:281-285.
41. Pharsight Corporation. WinNonlin Professional, Version 4.1. Mountain View, CA, USA: SAS Institute.
42. Barrett EL, Kwan HS. Bacterial reduction of trimethylamine oxide. Annu Rev Microbiol. 1985;39:131-149.
43. Cashman JR, Xiong Y, Lin J, et al. In vitro and in vivo inhibition of human flavin-containing monooxygenase form 3 (FMO3) in the presence of dietary indoles. Biochem Pharmacol. 1999;58:1047-1055.
44. Ayesh R, Mitchell SC, Zhang A, Smith RL. The fish odour syndrome: biochemical, familial, and clinical aspects. BMJ. 1993;307:655-657.
45. Rebouche CJ. Metabolic fate of dietary carnitine in humans. In: Carter AL, ed. Current Concepts in Carnitine Research. Boca Raton, Fla: CRC Press Inc; 1992:37-48.
46. Gudjonsson H, Li BU, Shug AL, Olsen WA. In vivo studies of intestinal carnitine absorption in rats. Gastroenterology. 1985;88:1880-1887.
47. Sahajwalla CG, Helton ED, Purich ED, Hoppel CL, Cabana BE. Comparison of L-carnitine pharmacokinetics with and without baseline correction following administration of single 20-mg/kg intravenous dose. J Pharm Sci. 1995;84:634-639.
48. Segre G, Bianchi E, Corsi M, D'Iddio S, Ghirardi O, Maccari F. Plasma and urine pharmacokinetics of free and of short-chain carnitine after administration of carnitine in man. Arzneimittelforschung. 1988;38:1830-1834.
49. Rizza V, Lorefice R, Rizza N, Calabrese V. Pharmacokinetics of L-carnitine in human subjects. In: Ferrari R, Dimauro S, Sherwood G, eds. L-carnitine and Its Role in Medicine: From Function to Therapy. New York, NY: Academic Press; 1992:63-77.
50. Mancinelli A, Longo A, Shanahan K, Evans AM. Disposition of L-carnitine and acetyl-L-carnitine in the isolated perfused rat kidney. J Pharmacol Exp Ther. 1995;274:1122-1128.
51. Marzo A, Arrigoni Martelli E, Mancinelli A, et al. Protein binding of L-carnitine family components. Eur J Drug Metab Pharmacokinet. 1991;Special Issue No III:364-368.
52. Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet. 2003;42:941-967.
53. Rowland M, Tozer T. Clinical Pharmacokinetics: Concepts and Applications. 3rd edition. Philadelphia, Pa: Lippincott Williams & Wilkins; 1995.
54. Sahajwalla CG, Helton ED, Purich ED, Hoppel CL, Cabana BE. Multiple-dose pharmacokinetics and bioequivalence of L-carnitine 330-mg tablet versus 1-g chewable tablet versus enteral solution in healthy adult male volunteers. J Pharm Sci. 1995;84:627-633.